An apparent assay hit may involve more than isolated molecules interacting with a target. Material can assemble into particles or other aggregates under experimental conditions. If those assemblies alter the assay, a reproducible response can still support the wrong molecular explanation. The central reading task is to separate the observed effect from the proposed mode of action.
Ask what form of material produces the response
Sassano and colleagues showed that known colloid-forming compounds could inhibit peptide- or protein-activated GPCR assays in an aggregation-dependent manner. Their work extends this interference question beyond soluble-enzyme screens to receptor-based measurements.Sassano and colleagues — Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors (opens in a new tab)
The materials studied there were not a demonstration that all peptide ligands aggregate. The relevant lesson is that a receptor readout can change without establishing the selective interaction proposed for an individual molecule.
When reading a hit claim, separate three statements: the preparation changed the readout, aggregates were observed, and aggregates caused the change. These statements require different evidence.
A study can establish the first two while leaving their causal relationship uncertain. Conversely, a failure to examine physical state leaves an aggregation explanation untested rather than disproved.
Look for agreement between physical and functional evidence
| Evidence type | Useful contribution | Remaining limitation |
|---|---|---|
| Particle measurement | Shows assemblies under measured conditions | Does not alone assign biological effect |
| Response comparison | Shows activity changes with a condition | That condition may change other factors |
| Independent readout | Tests a different detection route | May still share the same confounder |
The strength lies in how the observations connect. Physical measurements made in a different medium or concentration range may not describe the material present during the biological assay.
Likewise, if an intervention changes both particles and target activity, examine whether the study accounted for effects of the intervention itself. The comparison needs an interpretable reference.
Imagine a fictional study observing particles only at its highest tested concentration, where inhibition also first appears. That alignment makes aggregation a useful hypothesis, but coincidence at one condition does not establish the mechanism.
A reader should look for the next discriminating result rather than immediately assigning a definitive label to the compound.
Use peptide-specific evidence without generalising the scaffold
Taechalertpaisarn and colleagues’ 2026 study of mortiamide-related cyclic heptapeptides combined physical characterisation with functional counter-assays. The authors linked the observed bioactivity to aggregation and cautioned that the detailed route to cell death still required further work.Taechalertpaisarn and colleagues — Exploring Passive Permeability Profiles of Cyclic Heptapeptide Chemical Space Uncovers Bioactivity of Mortiamide Scaffold Driven by Colloidal Aggregation (opens in a new tab)
This is an example of a mechanism being narrowed by several lines of evidence. It is not a basis for labelling every cyclic peptide, or every hydrophobic peptide, an assay artefact.
Record the actual construct and tested conditions. A broad family name can conceal differences that matter to the physical state of the preparation.
Avoid both automatic acceptance and automatic dismissal
A steep concentration-response curve or broad activity across assays may raise questions, but neither feature independently proves aggregation. Treat such patterns as reasons to examine supporting evidence.
Nor does a clear-looking sample establish the absence of relevant assemblies. If the claim depends on molecular dispersion, identify the measurement that supports it rather than relying on an appearance description.
A careful summary can say that the assay response coincided with measured aggregation and changed in comparisons designed to assess that contribution. If the causal link remains incomplete, say which part is unresolved.
The aim is to retain useful observations while avoiding a premature target story. Distinguishing molecular activity from assembly-associated behaviour makes subsequent comparisons between studies more informative, especially when their media and exposure conditions differ.
Sources and further detail
- Sassano and colleagues — Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors (opens in a new tab)
Original 2013 abstract and discussion read through indexed PMC; author metadata checked. Brief example of aggregation-dependent assay effects, without procedural concentrations or a claim that the tested aggregators were peptide ligands.
- Taechalertpaisarn and colleagues — Exploring Passive Permeability Profiles of Cyclic Heptapeptide Chemical Space Uncovers Bioactivity of Mortiamide Scaffold Driven by Colloidal Aggregation (opens in a new tab)
Original article published 14 May 2026; abstract, aggregation results and conclusion read. Brief paraphrase preserves the unresolved cell-death mechanism. Evidence matrix and hypothetical concentration comparison are original.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.